EGFR Antibody
Duligotuzumab is a dual-targeting human IgG1 monoclonal antibody that simultaneously binds to both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) . Duligotuzumab exerts its antitumor effects by blocking these dual signaling pathways and by inducing antibody-dependent cellular cytotoxicity (ADCC), targeting tumors where EGFR/HER3 overexpression correlates with poor prognosis.
Product Specifications
Product Name Alternative
MEHD-7945A, Duligotumab, RG 7597
Target
EGFR
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Concentration
18.734 mg/mL
Purity
≥95% (May vary between batches)
Molecular Weight
144.77 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Escherichia coli Putative lipopolysaccharide biosynthesis O-acetyl transferase wbbJ (wbbJ)
Recombinant Escherichia coli Putative lipopolysaccharide biosynthesis O-acetyl transferase wbbJ (wbbJ)
Recombinant Escherichia coli Putative lipopolysaccharide biosynthesis O-acetyl transferase wbbJ (wbbJ)
Recombinant Escherichia coli Putative lipopolysaccharide biosynthesis O-acetyl transferase wbbJ (wbbJ)
Recombinant Escherichia coli Putative lipopolysaccharide biosynthesis O-acetyl transferase wbbJ (wbbJ)